These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 38853277)

  • 1. Cell surface CD55 traffics to the nucleus leading to cisplatin resistance and stemness by inducing PRC2 and H3K27 trimethylation on chromatin in ovarian cancer.
    Bharti R; Dey G; Khan D; Myers A; Huffman OG; Saygin C; Braley C; Richards E; Sangwan N; Willard B; Lathia JD; Fox PL; Lin F; Jha BK; Brown JM; Yu JS; Dwidar M; Joehlin-Price A; Vargas R; Michener CM; Longworth MS; Reizes O
    Mol Cancer; 2024 Jun; 23(1):121. PubMed ID: 38853277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exosomal miR-4516 derived from ovarian cancer stem cells enhanced cisplatin tolerance in ovarian cancer by inhibiting GAS7.
    Pan X; Shi X; Zhang H; Chen Y; Zhou J; Shen F; Wang J; Jiang R
    Gene; 2024 Nov; 927():148738. PubMed ID: 38955306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo.
    Hu S; Yu L; Li Z; Shen Y; Wang J; Cai J; Xiao L; Wang Z
    Cancer Biol Ther; 2010 Oct; 10(8):788-95. PubMed ID: 20686362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness.
    Muñoz-Galván S; Felipe-Abrio B; Verdugo-Sivianes EM; Perez M; Jiménez-García MP; Suarez-Martinez E; Estevez-Garcia P; Carnero A
    Mol Cancer; 2020 Jan; 19(1):7. PubMed ID: 31926547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineered 3D Model of Cancer Stem Cell Enrichment and Chemoresistance.
    Ward Rashidi MR; Mehta P; Bregenzer M; Raghavan S; Fleck EM; Horst EN; Harissa Z; Ravikumar V; Brady S; Bild A; Rao A; Buckanovich RJ; Mehta G
    Neoplasia; 2019 Aug; 21(8):822-836. PubMed ID: 31299607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
    Ramadoss S; Sen S; Ramachandran I; Roy S; Chaudhuri G; Farias-Eisner R
    Oncogene; 2017 Mar; 36(11):1537-1545. PubMed ID: 27694900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EZH2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells.
    Wen Y; Hou Y; Yi X; Sun S; Guo J; He X; Li T; Cai J; Wang Z
    Theranostics; 2021; 11(4):1795-1813. PubMed ID: 33408782
    [No Abstract]   [Full Text] [Related]  

  • 8. Integrin-linked kinase-frizzled 7 interaction maintains cancer stem cells to drive platinum resistance in ovarian cancer.
    Atwani R; Nagare RP; Rogers A; Prasad M; Lazar V; Sandusky G; Tong Y; Pin F; Condello S
    J Exp Clin Cancer Res; 2024 Jun; 43(1):156. PubMed ID: 38822429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
    Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
    Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD10
    Ffrench B; Gasch C; Hokamp K; Spillane C; Blackshields G; Mahgoub TM; Bates M; Kehoe L; Mooney A; Doyle R; Doyle B; O'Donnell D; Gleeson N; Hennessy BT; Stordal B; O'Riain C; Lambkin H; O'Toole S; O'Leary JJ; Gallagher MF
    Cell Death Dis; 2017 Oct; 8(10):e3128. PubMed ID: 29048400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors.
    Saygin C; Wiechert A; Rao VS; Alluri R; Connor E; Thiagarajan PS; Hale JS; Li Y; Chumakova A; Jarrar A; Parker Y; Lindner DJ; Nagaraj AB; Kim JJ; DiFeo A; Abdul-Karim FW; Michener C; Rose PG; DeBernardo R; Mahdi H; McCrae KR; Lin F; Lathia JD; Reizes O
    J Exp Med; 2017 Sep; 214(9):2715-2732. PubMed ID: 28838952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
    Ge T; Liu T; Guo L; Chen Z; Lou G
    Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalized Medicine-Based Approach to Model Patterns of Chemoresistance and Tumor Recurrence Using Ovarian Cancer Stem Cell Spheroids.
    Raghavan S; Mehta P; Ward MR; Bregenzer ME; Fleck EMA; Tan L; McLean K; Buckanovich RJ; Mehta G
    Clin Cancer Res; 2017 Nov; 23(22):6934-6945. PubMed ID: 28814433
    [No Abstract]   [Full Text] [Related]  

  • 14. Frizzled-7 Identifies Platinum-Tolerant Ovarian Cancer Cells Susceptible to Ferroptosis.
    Wang Y; Zhao G; Condello S; Huang H; Cardenas H; Tanner EJ; Wei J; Ji Y; Li J; Tan Y; Davuluri RV; Peter ME; Cheng JX; Matei D
    Cancer Res; 2021 Jan; 81(2):384-399. PubMed ID: 33172933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
    Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
    Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer-associated mesothelial cells promote ovarian cancer chemoresistance through paracrine osteopontin signaling.
    Qian J; LeSavage BL; Hubka KM; Ma C; Natarajan S; Eggold JT; Xiao Y; Fuh KC; Krishnan V; Enejder A; Heilshorn SC; Dorigo O; Rankin EB
    J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34396988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of PI3K/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer.
    Zhang M; Wang J; Guo Y; Yue H; Zhang L
    J Ovarian Res; 2023 Dec; 16(1):240. PubMed ID: 38115063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin-induced PANDAR-Chemo-EVs contribute to a more aggressive and chemoresistant ovarian cancer phenotype through the SRSF9-SIRT4/SIRT6 axis.
    Wang H; Li Y; Wang Y; Shang X; Yan Z; Li S; Bao W
    J Gynecol Oncol; 2024 Mar; 35(2):e13. PubMed ID: 37921598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin induces stemness in ovarian cancer.
    Wiechert A; Saygin C; Thiagarajan PS; Rao VS; Hale JS; Gupta N; Hitomi M; Nagaraj AB; DiFeo A; Lathia JD; Reizes O
    Oncotarget; 2016 May; 7(21):30511-22. PubMed ID: 27105520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enrichment for chemoresistant ovarian cancer stem cells from human cell lines.
    Cole JM; Joseph S; Sudhahar CG; Cowden Dahl KD
    J Vis Exp; 2014 Sep; (91):51891. PubMed ID: 25285606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.